

Repegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: Not specified

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- age 8 to 45 years - recently diagnosed with type 1 diabetes (T1D) within the past 100 days - have at least one blood test showing an immune response associated with T1D and some remaining insulin production - see link to ClinicalTrials.gov for complete Inclusion criteria

Exclusion Criteria:

- current or recent serious infection, including tuberculosis, HIV, or hepatitis B or C - currently taking medications that suppress the immune system or have recently received certain immune-modulating treatments - history of certain serious heart conditions, cancer, or organ transplant - currently pregnant or breastfeeding, or planning to become pregnant during the study - see link to ClinicalTrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:

Diabetes & Endocrine

Keywords:

T1D, type 1 diabetes

More Information

Description: This study is looking at whether repegaldesleukin can help preserve insulin-producing cells in people who were recently diagnosed with type 1 diabetes. Participants will receive treatment every 2 weeks for 26 weeks, followed by a 6-month follow-up period.

Study Contact: Veronica Jones-Carr - jone2678@umn.edu

Principal Investigator: Antoinette Moran

Phase: PHASE2

IRB Number: STUDY00027051

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.